Telix pharmaceutical/$TLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Telix pharmaceutical
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Ticker
$TLX
Sector
Primary listing
Industry
Biotechnology
Headquarters
North Melbourne, Australia
Employees
423
Website
TLX Metrics
BasicAdvanced
$4.7B
146.12
$0.10
2.43
-
Price and volume
Market cap
$4.7B
Beta
2.43
52-week high
$30.36
52-week low
$13.61
Average daily volume
55K
Financial strength
Current ratio
2.776
Quick ratio
2.598
Long term debt to equity
98.548
Total debt to equity
102.329
Interest coverage (TTM)
11.30%
Profitability
EBITDA (TTM)
57.576
Gross margin (TTM)
61.79%
Net profit margin (TTM)
6.37%
Operating margin (TTM)
10.46%
Effective tax rate (TTM)
10.95%
Revenue per employee (TTM)
$1,216,190
Management effectiveness
Return on assets (TTM)
5.33%
Return on equity (TTM)
13.92%
Valuation
Price to earnings (TTM)
146.118
Price to revenue (TTM)
8.936
Price to book
12.35
Price to tangible book (TTM)
46.15
Price to free cash flow (TTM)
-1,281.303
Free cash flow yield (TTM)
-0.08%
Free cash flow per share (TTM)
-1.08%
Growth
Revenue change (TTM)
55.85%
Earnings per share change (TTM)
798.14%
3-year revenue growth (CAGR)
368.92%
3-year earnings per share growth (CAGR)
-20.27%
Bulls say / Bears say
Telix Pharmaceuticals reported a record revenue of $517 million in FY2024, marking a 55% increase, driven by the expansion of its cancer imaging portfolio. (stocktitan.net)
Wedbush initiated coverage on Telix with an 'outperform' rating and a price target of $22.00, indicating confidence in the company's growth prospects. (webull.com)
William Blair raised its FY2025 earnings estimate for Telix to $0.83 per share, reflecting optimism about the company's financial performance. (etfdailynews.com)
William Blair reduced its FY2026 earnings estimate for Telix to $1.03 per share, down from $1.05, suggesting potential concerns about future earnings growth. (defenseworld.net)
The stock has experienced volatility, with a 52-week high of $30.36 and a low of $13.61, indicating potential instability in investor sentiment. (cnbc.com)
Despite strong revenue growth, the company's reliance on a limited product portfolio could pose risks if competitors introduce superior alternatives or if regulatory challenges arise.
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TLX News
AllArticlesVideos
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Business Wire·20 hours ago
Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire·21 hours ago
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Telix pharmaceutical stock?
Telix pharmaceutical (TLX) has a market cap of $4.7B as of July 25, 2025.
What is the P/E ratio for Telix pharmaceutical stock?
The price to earnings (P/E) ratio for Telix pharmaceutical (TLX) stock is 146.12 as of July 25, 2025.
Does Telix pharmaceutical stock pay dividends?
No, Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next Telix pharmaceutical dividend payment date?
Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Telix pharmaceutical?
Telix pharmaceutical (TLX) has a beta rating of 2.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.